Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001990115 | SCV002232010 | uncertain significance | Cohen syndrome | 2021-03-16 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals with VPS13B-related conditions. This variant is present in population databases (rs398124336, ExAC 0.002%). This sequence change replaces glycine with glutamic acid at codon 2114 of the VPS13B protein (p.Gly2114Glu). The glycine residue is weakly conserved and there is a moderate physicochemical difference between glycine and glutamic acid. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The glutamic acid amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |